-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Class 1.
2020 year data related dementia studies show that China's 60 or more years old elderly patients with dementia, about 1507 people, including Alzheimer's disease (commonly known as "senile dementia") in patients with 983 million people, accounting for 60 or more years old population 3.
In 2008 , Dr.
In 2012 , under the support and auspices of Guangdong South China New Drug Creation Center, AD16 completed preclinical research.
In the recently concluded phase I clinical trial, AD16 showed very good overall safety and tolerability, no dose-related toxicity was observed, all treatment-related adverse events were grade 1/2 , and no serious adverse events occurred.
AD16 is expected to become China's first anti-neurological inflammation treatment of Alzheimer's disease, benefiting tens of millions of Alzheimer's patients
